Interés Humano

Johnson & Johnson solicita a la FDA que autorice un refuerzo de su vacuna contra la covid-19

Laboratorio señala que una segunda dosis de su inmunizante aumenta a 94% los niveles de protección

(FILES) In this file photo taken on August 07, 2021 (FILES) In this file photo taken on August 7, 2021, a dose of the Johnson and Johnson Covid-19 vaccine is prepared at a mobile vaccination clinic at the Weingart East Los Angeles YMCA in Los Angeles, California. - Drug maker Johnson & Johnson asked the US Federal Drug Administration on October 5, 2021, to authorize booster shots of its Covid-19 vaccine for people over the age of 18. "Our clinical program has found that a booster of our Covid-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent," said Mathai Mammen, global head of research and development at J&J. (Photo by Patrick T. FALLON / AFP)
(FILES) In this file photo taken on August 07, 2021 (FILES) In this file photo taken on August 7, 2021, a dose of the Johnson and Johnson Covid-19 vaccine is prepared at a mobile vaccination clinic at the Weingart East Los Angeles YMCA in Los Angeles, California. - Drug maker Johnson & Johnson asked the US Federal Drug Administration on October 5, 2021, to authorize booster shots of its Covid-19 vaccine for people over the age of 18. "Our clinical program has found that a booster of our Covid-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent," said Mathai Mammen, global head of research and development at J&J. (Photo by Patrick T. FALLON / AFP) PATRICK T. FALLON

Washington. El laboratorio Johnson & Johnson (J&J) solicitó este martes a la Administración Federal de Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) que autorice un refuerzo de su vacuna contra la covid-19 para personas mayores de 18 años.

“Nuestro programa clínico ha descubierto que un refuerzo de nuestra vacuna covid-19 aumenta a 94% los niveles de protección para aquellos que han recibido nuestra vacuna de dosis única”, afirmó Mathai Mammen, director global de investigación y desarrollo de J&J.

‌
‌

‌

‌
‌

‌

‌